Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Nanoparticle-Based Tumor Theranostics with Molecular Imaging

Nanotheranostics for Image-Guided Cancer Treatment

The Current Status and Future Directions on Nanoparticles for Tumor Molecular Imaging

Multiplexed Imaging with Coordination Nanoparticles for Cancer Diagnosis and Therapy

Imaging-guided precision oncotherapy mediated by nanoprobes: From seeing to curing

Molecular Imaging and Therapy of Cancer with Radiolabeled Nanoparticles.

Molecular Image-Guided Theranostic and Personalized Medicine 2013

Nanomedicine For Drug Delivery And Imaging: A Promising Avenue For Cancer Therapy And Diagnosis Using Targeted Functional Nanoparticles

Nanotheranostics With the Combination of Improved Targeting, Therapeutic Effects, and Molecular Imaging

Recent progress of nanotechnology-based theranostic systems in cancer treatments

Molecularly Near-Infrared Fluorescent Theranostics for in Vivo Tracking Tumor-Specific Chemotherapy

The role of imaging in targeted delivery of nanomedicine for cancer therapy

Nanoparticle Probes And Molecular Imaging In Cancer

Bioresponsive Nanomaterials: Recent Advances in Cancer Multimodal Imaging and Imaging-Guided Therapy

Cancer-Targeted Nanotheranostics: Recent Advances and Perspectives

Positron Emission Tomography and Nanotechnology: A Dynamic Duo for Cancer Theranostics

Activable Multi-Modal Nanoprobes for Imaging Diagnosis and Therapy of Tumors

Intelligent nanomaterials for cancer therapy: recent progresses and future possibilities

Magnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided Approaches

Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes

How Do Bismuth-Based Nanomaterials Function as Promising Theranostic Agents for the Tumor Diagnosis and Therapy?